Bayer Drug Prices To Be Monitored By HHS Under Medicaid Fraud Settlement
Executive Summary
Bayer will provide states and the federal government with the average selling prices of its drugs to help them set reasonable reimbursement rates under a tentative settlement agreement with the Justice Department.
You may also be interested in...
AWP Settlements Unlikely To Resolve Pricing Issue, State Fraud Chief Says
Federal health care fraud prosecutions will not be sufficient to resolve the issues surrounding AWP price reporting, National Association of State Medicaid Fraud Control Units President Christopher Abruzzo told the 340B Coalition annual conference in Washington, D.C. July 16
AWP Settlements Unlikely To Resolve Pricing Issue, State Fraud Chief Says
Federal health care fraud prosecutions will not be sufficient to resolve the issues surrounding AWP price reporting, National Association of State Medicaid Fraud Control Units President Christopher Abruzzo told the 340B Coalition annual conference in Washington, D.C. July 16
GSK, Bayer Will Audit Sales Contracts Under “Best Price” Rebate Settlement
Bayer will use an outside auditing firm to review its payments to managed care companies to ensure that the company is not disguising rebate payments